Paradigm Biopharmaceuticals Ltd. (ASX:PAR) has entered voluntary administration after its Board resolved to appoint Hayden White and Chris Pattinson of FTI Consulting as Voluntary Administrators, effective 29 September 2026, pursuant to section 436A of the Corporations Act 2001 (Cth), with the support of Obsidian Global GP, LLC.
Key Points
- Hayden White and Chris Pattinson of FTI Consulting appointed as Voluntary Administrators effective 29 September 2026.
- The Board intends to work with Obsidian Global GP, LLC and Administrators to develop a Deed of Company Arrangement (DOCA) for creditor consideration.
- The Phase 3 PARA_OA_012 clinical trial will not proceed following an interim efficacy result falling below the pre-specified threshold required for continuation.
- The Company's securities remain suspended from trading on the ASX and are expected to remain suspended during the administration.
- The overall clinical review and restructuring process is expected to take at least eight weeks from the Administrators' appointment, with the timetable subject to change.
Voluntary Administration Appointment and DOCA Proposal
The Board resolved to appoint FTI Consulting's Hayden White and Chris Pattinson as Voluntary Administrators following discussions with Obsidian Global GP, LLC regarding the financial implications of the interim clinical trial outcome and potential restructuring options. The Board stated that the Company requires time to resolve the mismatch between current liabilities payable in the short term and the long-term value of its intellectual property portfolio. The Board intends, with the cooperation of the Administrators, to work with Obsidian and other relevant stakeholders to develop a DOCA proposal for consideration by the Administrators and creditors. The filing states there is no certainty that a DOCA will be approved or implemented, or what the outcome will be for shareholders and creditors.
Phase 3 Clinical Trial Outcome and Data Review
According to the filing, the Phase 3 PARA_OA_012 trial will not proceed as planned following the interim efficacy result falling below the pre-specified threshold required for continuation. The Company stated it intends to continue analysing the available study data and reviewing its clinical program during the restructuring process, subject to the Administrators' assessment and available resources. This work is intended to improve understanding of the interim outcome, including the impact of missing data, and to inform the assessment of future development and commercial options. During the administration, the powers of the Company's officers are suspended.
Administration Timetable and Trading Suspension
The Company currently expects the overall clinical review and restructuring process to take at least eight weeks from the appointment of the Administrators, with the filing noting that the process may take longer. The estimate is subject to the progress of the review, the development and consideration of any restructuring proposal, and any necessary approvals or extensions to statutory timeframes. The Administrators will take control of the Company's business, property and affairs and will undertake an independent assessment of its financial position. The timetable for any reinstatement of trading remains uncertain and is subject to ASX requirements and approval.





Please wait processing your request...